Skip to Main Content
Contribute Try STAT+ Today

In August, Pear Therapeutics, the company at the forefront of creating prescription software to treat health conditions, announced that it had landed a deal with Optum Rx, which administers pharmacy benefits for millions of people nationwide.

It was a coup for an 8-year-old company, which had recently announced its intention to go public in a $1.6 billion deal, despite projecting just $4 million in revenue for 2021. According to the celebratory announcement, Pear’s three commercial smartphone apps, which deliver cognitive behavioral therapy for the treatment of substance use disorder, opioid use disorder, and insomnia, would have “formulary availability” with the country’s third-largest pharmacy benefits manager.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment